lumiracoxib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
selective cyclo-oxygenase inhibitors	1618	220991-20-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: joicela lumiracoxib prexige	A selective non-steroidal anti-inflammatory drug (NSAID) that belongs to the group cyclo-oxygenase 2 (COX-2) inhibitors. It blocks the COX-2 enzyme, resulting in a reduction in the production of prostaglandins, substances that are involved in the inflammation process. Molecular weight: 293.72 Formula: C15H13ClFNO2 CLOGP: 4.50 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 49.33 ALOGS: -4.73 ROTB: 4

Molecule

Description

Molfile Inchi Smiles

Synonyms:

joicela
lumiracoxib
prexige

A selective non-steroidal anti-inflammatory drug (NSAID) that belongs to the group cyclo-oxygenase 2 (COX-2) inhibitors. It blocks the COX-2 enzyme, resulting in a reduction in the production of prostaglandins, substances that are involved in the inflammation process.

Molecular weight: 293.72
Formula: C15H13ClFNO2
CLOGP: 4.50
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 49.33
ALOGS: -4.73
ROTB: 4

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	74 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Sept. 12, 2003	UK Medicines and Healthcare Products Regulatory Agency (MHRA)	Novartis Pharmaceuticals UK Limited

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M01AH06	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Coxibs
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D052246	Cyclooxygenase 2 Inhibitors
MeSH PA	D016861	Cyclooxygenase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory agent
CHEBI has role	CHEBI:50629	COX-2 inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Osteoarthritis	indication	396275006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.24	acidic
pKa2	0.42	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	INHIBITOR	Ki	6.49	CHEMBL	SCIENTIFIC LITERATURE
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN		IC50	8.15	CHEMBL
Prostaglandin G/H synthase 2	Enzyme		PGH2_MOUSE		IC50	7.40	CHEMBL

External reference:

ID	Source
D03714	KEGG_DRUG
C1176415	UMLSCUI
CHEBI:73044	CHEBI
LUR	PDB_CHEM_ID
CHEMBL404108	ChEMBL_ID
DB01283	DRUGBANK_ID
C473384	MESH_SUPPLEMENTAL_RECORD_UI
151166	PUBCHEM_CID
2897	IUPHAR_LIGAND_ID
8151	INN_ID
V91T9204HU	UNII
011158	NDDF
422506000	SNOMEDCT_US
424967004	SNOMEDCT_US

Pharmaceutical products:

None